Create Medicines Inc. closed a $122 million series B financing round to support its pipeline of therapies that use mRNAs delivered via liquid nanoparticles to express chimeric antigen receptors (CARs) in T cells, NK cells and myeloid cells inside the body of patients. The Cambridge, Mass.-based company estimates the capital will last through 2028, providing the opportunity for multiple clinical readouts of its various products.